Unibest 优贝德
← Back to patent-cliff list

CAS 2222752-06-7

4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

Codes:SELP-021、SELP-025

Application context (from source-drug indications)

实体瘤塞普替尼甲状腺髓样癌塞普替尼非小细胞肺癌塞普替尼甲状腺瘤塞普替尼

Source drugs (routes using this intermediate)

DrugTierExpiry
塞普替尼SelpercatinibTier C — Watch / trade2032

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

塞普替尼优化路线steps: 2total yield: 41.4 g (Selpercatinib)
6-methoxynicotinaldehyde→4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile→1-bromo-2-methylpropan-2-ol→4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.